X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
With a shared goal of bringing cell therapies to patients with solid tumours, Neogene’s expertise in TCR-T discovery, development and manufacturing will strengthen AstraZeneca’s ambition to transform outcomes for patients.
Lead Product(s): TCR Therapy
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: DiscoveryProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: AstraZeneca
Deal Size: $320.0 million Upfront Cash: $200.0 million
Deal Type: Acquisition November 29, 2022
Details:
NT-125, designed to contain up to five distinct neoantigen-specific TCRs per patient in single cell product of highly functional engineered T cells, allowing multiple neoantigens by HLA molecules targeted with goal to create a more impactful TCR therapy for more patients.
Lead Product(s): NT-125
Therapeutic Area: Oncology Product Name: NT-125
Highest Development Status: IND EnablingProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 10, 2022
Details:
Acquisition will provide access to next-generation T-cell receptor therapies with promising potential for targeting solid tumours to AstraZeneca. TCR-based Therapies can recognise intracellular targets, including cancer-specific mutations.
Lead Product(s): TCR-based Therapy
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: DiscoveryProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: AstraZeneca
Deal Size: $320.0 million Upfront Cash: $320.0 million
Deal Type: Acquisition January 16, 2022
Details:
The companies will leverage Neogene’s expertise in targeting tumor neo-antigens, mutated proteins found in cancer cells together with Twist’s DNA synthesis platform and product lines to develop personalized CAR) T cell therapies and TCR therapies for patients with cancer.
Lead Product(s): CAR-T cell therapy
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: DiscoveryProduct Type: Cell and Gene therapy
Recipient: Twist Bioscience
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Partnership October 13, 2020
Details:
Neogene’s proprietary technology platform identifies specific T cell receptor (TCR) genes from routine tumor samples using state-of-the-art synthetic biology tools.
Lead Product(s): Neo-Antigen T Cell Receptor
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: PreclinicalProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: EcoR1 Capital
Deal Size: $110.0 million Upfront Cash: Undisclosed
Deal Type: Series A Financing September 14, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
